Mineralys Therapeutics Inc options imply 21.7% move in share price post-earnings
Options trading for Mineralys Therapeutics Inc (MLYS) indicates an anticipated 21.7% movement in its share price following its upcoming earnings release. The normal volume of pre-earnings options shows puts significantly outnumbering calls (56:1). This implied volatility suggests a much larger move than the company's historical median of 4.2% over the last eight quarters.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Rating of "Moderate Buy" by Analysts
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has received an average recommendation of "Moderate Buy" from eight ratings firms, with an average twelve-month price objective of $47.4286. Recent analyst reports have seen price targets boosted, though one firm reiterated a "sell" rating. Insider sales activity by a company executive and CFO decreased their respective stock holdings, while institutional investors and hedge funds have recently increased their positions in the company.
David Malcom Rodman Sells 417 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), recently sold 417 shares of the company's stock for $27.59 per share, totaling $11,505.03. This sale decreased his position by 0.94%, leaving him with 44,089 shares valued at approximately $1.22 million. The company's stock traded higher at $27.94 with an average analyst rating of "Moderate Buy" and a target price of $47.43, despite trading below its 50- and 200-day moving averages.
Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505
Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics (MLYS) sold 417 shares of company stock for $11,505 on February 17, 2026, after exercising options for the same number of shares. This transaction occurred via a Rule 10b5-1 trading plan and follows a significant 191% surge in the stock over the past year. Analysts rate Mineralys as a Strong Buy, with the company set to report earnings on March 18.
Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505
Mineralys Therapeutics Chief Medical Officer, David Malcom Rodman, sold 417 shares of common stock for $11,505 on February 17, 2026, after exercising options for the same number of shares. This transaction occurred after the company's stock surged 191% over the past year, and analysts rate it a "Strong Buy" with price targets between $42 and $56. The company is also making significant progress with its lead asset, lorundrostat, for hypertension treatment, with an NDA preparation underway and recognition of its Phase 3 trial in JAMA.
Why (MLYS) Price Action Is Critical for Tactical Trading
Mineralys Therapeutics Inc. (NASDAQ: MLYS) is showing weak near and mid-term sentiment, despite a positive long-term outlook, with a breakdown currently underway suggesting lower levels are expected. The article presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, alongside multi-timeframe signal analysis indicating varying support and resistance levels. These strategies provide specific entry, target, and stop-loss zones for tactical trading decisions.
Mineralys Therapeutics Grants Inducement Equity Awards to Two New Employees
Mineralys Therapeutics Inc. (Nasdaq: MLYS) announced that its board compensation committee granted inducement stock option and restricted stock unit awards to two new non-executive employees on February 9, 2026. These awards, covering options for 33,504 shares and RSUs for 25,128 shares, are designed to attract and retain talent, vesting over four years subject to continued employment. The company, headquartered in Radnor, PA, focuses on developing treatments for hypertension and related conditions.
David Malcom Rodman Sells 14,055 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), sold 14,055 shares of the company's stock on February 13th for approximately $385,669. This transaction reduced his direct ownership to 44,089 shares, marking a 24.17% decrease in his stake. The stock traded down 0.9% to $27.60, below its 50- and 200-day moving averages, while analysts maintain a "Moderate Buy" consensus with an average price target of $47.43.
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 6,349 Shares
Mineralys Therapeutics (NASDAQ:MLYS) insider David Malcom Rodman sold 6,349 shares of the company's stock on February 12th for over $184,000, reducing his stake by 11.18%. This sale is part of a series of large transactions by Rodman since early January. Despite the insider selling, analysts maintain a "Moderate Buy" rating for MLYS with an average price target of $47.43.
Mineralys Therapeutics MLYS officer sells $569k in stock
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics (NASDAQ:MLYS), sold 14,676 shares for approximately $569,809 on February 12-13, 2026, while also acquiring 14,056 shares through option exercises for $102,340. These transactions were part of a pre-arranged trading plan, leaving Rodman with 44,089 direct shares. The company is advancing its lead asset, lorundrostat, for hypertension, with positive clinical trial results and a raised price target from Stifel, despite recent insider sales by other executives.
Mineralys Therapeutics MLYS officer sells $569k in stock
Mineralys Therapeutics Chief Medical Officer, David Malcom Rodman, sold shares worth approximately $569,809 in mid-February 2026, while also acquiring shares through option exercises for $102,340, all under a pre-arranged trading plan. This comes as the company's lead asset, lorundrostat, received recognition for its Phase 3 trial, leading to an increased price target from Stifel, despite previous insider sales by other executives.
Mineralys Therapeutics Breaks Below 200-Day Moving Average - Notable for MLYS
Shares of Mineralys Therapeutics Inc (MLYS) fell below their 200-day moving average of $27.66 on Friday, trading as low as $27.33 per share. Despite this, the stock was trading up about 1.5% on the day. The article notes the company's 52-week trading range and current price relative to its moving average.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. announced inducement stock option and restricted stock unit awards to two new non-executive employees. These awards, granted under the company's 2025 Employment Inducement Incentive Award Plan, cover 33,504 shares for options and 25,128 shares for restricted stock units, vesting over four-year periods. The grants are in accordance with Nasdaq Listing Rule 5635(c)(4) to induce their employment.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics announced inducement stock option and restricted stock unit awards to two new non-executive employees, granted on February 9, 2026. These awards, totaling 33,504 stock options and 25,128 restricted stock units, were issued under the company's 2025 Employment Inducement Incentive Award Plan. The awards are subject to vesting schedules and comply with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares
Mineralys Therapeutics (NASDAQ:MLYS) insider David Malcom Rodman sold 2,171 shares of the company's stock on February 9th for $65,585.91, reducing his position by 4.13%. This is part of a series of large sales by Rodman since early January, totaling millions of dollars. Despite the insider selling, analysts maintain a "Moderate Buy" rating for MLYS with an average target price of $47.43.
Biotech Mineralys offers 4-year stock awards to new hires
Mineralys Therapeutics announced the granting of inducement equity awards to two new non-executive employees on February 9, 2026. These awards, issued under the company's 2025 Employment Inducement Incentive Award Plan, include stock options for 33,504 shares and 25,128 restricted stock units. The equity awards will vest over a four-year period, with specific schedules for options and RSUs, in accordance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics announced inducement stock option awards for 33,504 shares and restricted stock unit awards for 25,128 shares to two new non-executive employees. These awards, granted on February 9, 2026, are part of the company's 2025 Employment Inducement Incentive Award Plan and vest over a four-year period. The grants were made to induce the new employees to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Candriam S.C.A.
Candriam S.C.A. reduced its stake in Mineralys Therapeutics by 31.1% in Q3, selling over 256,000 shares, and institutional investors now own 84.46% of the company. Additionally, insiders sold a significant amount of shares totaling over $56 million in the last three months, though corporate insiders still own 33.24% of the stock. Despite this selling activity, analysts largely maintain a "Moderate Buy" rating for MLYS, with a consensus target price of $47.43.
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS)
Mineralys Therapeutics (NASDAQ:MLYS) experienced unusually high put option trading activity, with volume increasing by over 3,000%. This occurred amidst significant insider selling, including a 1,000,000-share sale by a director, totaling $71.1 million in insider sell-offs last quarter. Despite this, institutional investors hold a large stake, and analysts maintain a "Moderate Buy" rating with a consensus price target of $47.43.
Mineralys Therapeutics (MLYS) to Release Earnings on Wednesday
Mineralys Therapeutics (MLYS) is expected to release its earnings before market open on Wednesday, February 11th, with analysts forecasting a loss of ($0.57) per share. The company previously reported an EPS of ($0.52) for the quarter ending November 10th, beating estimates. Recent insider transactions include share sales by CEO Jon Congleton and CFO Adam Scott Levy in January, while institutional investors and hedge funds have adjusted their holdings.
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD
Mineralys Therapeutics announced positive topline results from its Phase 2 "Advance-HTN" trial of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension and stage 3/4 chronic kidney disease. The trial met its primary endpoint, showing significant reductions in systolic blood pressure compared to placebo. Lorundrostat was also generally well-tolerated, demonstrating its potential as a treatment for this challenging patient population.
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones
Mineralys Therapeutics (MLYS) has filed its New Drug Application (NDA) for lorundrostat, following positive results from three clinical trials (Explore-CKD, Launch-HTN, and Advance-HTN) demonstrating 24-hour blood pressure control and safety. The company anticipates reporting topline results from its Phase 2 Explore-OSA trial in Q1 2026. Analysts from Bank of America and Stifel have raised their price targets on MLYS, citing positive Q3 2025 results and a confirmed cash runway into 2027, with BofA highlighting the potential for a commercialization and development partner as a major catalyst.
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones
Mineralys Therapeutics (MLYS) has filed its NDA for lorundrostat following positive clinical trial results from Explore-CKD, Launch-HTN, and Advance-HTN, which demonstrated 24-hour blood pressure control and safety. The company expects topline results from its Phase 2 Explore-OSA trial in Q1 2026 and continues to gather long-term data. Analysts at Bank of America and Stifel have raised their price targets for MLYS, citing potential catalysts like a commercialization and development partner.
11 Best High Short Interest Stocks With Biggest Upside Potential
The article identifies Mineralys Therapeutics Inc. (NASDAQ: MLYS) as one of the top high short interest stocks with significant upside potential. The company's recent clinical milestones for its drug lorundrostat, including positive trial completions and a late 2025 NDA filing, have contributed to its outlook. Analyst price targets have been raised, with Bank of America setting $46 and Stifel $52, both maintaining Buy ratings, citing the potential for strategic partnerships and the company's strong cash runway.
11 Best High Short Interest Stocks With Biggest Upside Potential
This article identifies high short interest stocks with significant upside potential, focusing on Mineralys Therapeutics Inc. (NASDAQ:MLYS) as an example. It details MLYS's clinical milestones for its drug lorundrostat, including successful trials and upcoming Phase 2 results. The company has received raised price targets and "Buy" ratings from analysts at Bank of America and Stifel, citing a strong cash runway and potential for a commercialization partner.
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Uncovering a 53.98% Potential Upside in Biotech
Mineralys Therapeutics, Inc. (MLYS) is a biotech company focused on developing treatments for diseases related to dysregulated aldosterone, such as hypertension and chronic kidney disease, with its lead candidate lorundrostat in clinical trials. Despite being a clinical-stage company without traditional valuation metrics, analysts have issued eight buy ratings and one hold, projecting a 53.98% potential upside to an average target price of $50.88. The company's strategic reinvestment in its pipeline, coupled with strong analyst support, positions it as a high-risk, high-reward investment opportunity in the biotechnology sector.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Mineralys Therapeutics (NASDAQ:MLYS) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $47.43. Despite significant insider selling over the past 90 days, institutional investors have increased their holdings. The company recently reported better-than-expected Q3 earnings and has a market capitalization of $2.59 billion.
Avoiding Lag: Real-Time Signals in (MLYS) Movement
This article provides a real-time analysis of Mineralys Therapeutics Inc. (MLYS), highlighting divergent market sentiment and a challenging support level. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and emphasizes the potential for an exceptional risk-reward setup. Stock Traders Daily offers real-time signals, risk-reward ratios, and customizable alerts to registered users.
Mineralys Therapeutics Inc call volume above normal and directionally bullish
Mineralys Therapeutics (MLYS) has shown unusually high and bullish call option activity, with 1,300 calls trading, which is three times the expected volume. This activity led to a nearly 6-point increase in implied volatility to 90.78%. The most active options are the June 2026 $35 calls and March 2026 $40 calls, and the company's Q4 earnings report is expected on February 12th.
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook
Mineralys Therapeutics' recent earnings call highlighted a positive outlook, discussed recent company developments, and provided an update on its financial performance. The company's future prospects and strategic initiatives were also key topics during the call.
Rodman sells Mineralys (MLYS) shares for $13,353
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics (MLYS), sold 416 shares of company stock for $13,353, while also exercising options to acquire an equal number of shares. The transaction occurred under a Rule 10b5-1 trading plan. Despite recent insider sales by CEO Jon Congleton and CFO Scott Levy, the company demonstrated strong performance with a narrower-than-expected Q3 2025 loss and positive clinical trial results for its lead drug, lorundrostat, leading to a "Buy" rating and increased price target from Stifel.
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), sold 416 shares of the company's stock on January 20th, reducing his ownership by 0.82%. This is part of a series of disposals in January totaling approximately 290,762 shares worth about $10.2 million. The company's stock recently traded at $31.93, has significant institutional ownership, and a consensus analyst rating of "Moderate Buy."
Are Mineralys Therapeutics’ (MLYS) Executive Stock Plans Aligned With Lorundrostat’s Emerging Investment Story?
Mineralys Therapeutics (MLYS) recently reported strong Q3 2025 results and is advancing its drug lorundrostat towards NDA for hypertension and chronic kidney disease. Concurrently, senior executives engaged in pre-arranged stock sales. The article examines how lorundrostat's clinical progress and regulatory path influence MLYS's investment narrative, noting potential financing risks despite positive drug developments.
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,709 Shares of Stock
Mineralys Therapeutics (NASDAQ:MLYS) insider David Malcom Rodman sold 7,709 shares of the company's stock on January 13th for $32.75 per share, totaling over $252,000. This sale is part of a series of transactions in early January, reducing his direct ownership by 11.09%. The article notes the company's market performance, analyst ratings, and institutional investor activity.
David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), recently sold 11,367 shares of the company's stock, valued at approximately $370,678. This sale is part of a series of large transactions in early January, significantly reducing his holdings by 18.39%. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $47.43, and institutional investors hold a substantial 84.46% stake in the company.
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $72,195.90 in Stock
Mineralys Therapeutics (NASDAQ:MLYS) insider David Malcom Rodman sold 2,170 shares of the company's stock on January 9th for a total of $72,195.90, reducing his position by 3.39%. This sale is part of several recent transactions by Rodman, totaling approximately $9.98 million in proceeds across 281,639 shares. Despite the insider selling, analysts maintain a "Moderate Buy" rating for MLYS, with an average target price of $47.43, while institutional investors hold a significant 84.46% of the stock.
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $529,618.32 in Stock
Mineralys Therapeutics CEO Jon Congleton sold 16,236 shares of the company's stock for $529,618.32, reducing his stake by 2.48%. This sale occurred on January 12th, adding to a previous larger sale in November. Despite the insider selling, analysts maintain a "Moderate Buy" consensus for MLYS, with an average price target of $47.43.
Mineralys Therapeutics MLYS officer sells $277k in stock
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 8,518 shares of common stock for approximately $277,339, while simultaneously exercising options to acquire the same number of shares. These transactions occurred on January 9 and 12, 2026, and Rodman now directly owns 61,804 shares. The company has shown impressive returns over the past year and recently reported better-than-expected earnings, with analyst price targets suggesting potential upside.
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock
Adam Scott Levy, CFO of Mineralys Therapeutics (MLYS), sold 10,758 shares of common stock for approximately $345,723 on January 12, 2026, as part of a pre-arranged trading plan. Despite a recent stock decline, MLYS has shown an impressive 261% return over the past year. This sale follows strong Q3 2025 earnings and positive developments for their lead drug, lorundrostat, which has bolstered investor sentiment despite recent insider sales.
Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton sold 16,236 shares of common stock for approximately $529,639 on January 12, 2026. These sales, executed under a pre-arranged trading plan, occurred as the company reported a narrower-than-expected Q3 2025 loss and received a price target increase from Stifel due to strong clinical trial results for its lead drug, lorundrostat. Despite recent insider sales from multiple executives, the company's outlook is bolstered by its promising clinical performance and financial developments.
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therap
Mineralys Therapeutics Inc CEO Jon Congleton sold 16,236 shares of the company on January 12, 2026, reducing his total holdings to 639,151 shares. This transaction is part of a larger trend of insider selling at the company over the past year, with 24 insider sells compared to 6 insider buys. The company's stock was trading at $32.62 per share at the time of the sale, giving it a market capitalization of $2.607 billion.
Discipline and Rules-Based Execution in MLYS Response
This article analyzes Mineralys Therapeutics Inc. (NASDAQ: MLYS) using AI models, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It identifies a significant risk-reward setup and provides institutional trading strategies for different risk profiles. The analysis includes support, resistance, and signal strength across various time horizons.
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced its third-quarter 2025 financial results and provided a corporate update, including preparations for an NDA submission for lorundrostat by early 2026. The company completed a public equity financing of approximately $287.5 million, raising its cash, cash equivalents, and investments to $593.6 million, sufficient to fund operations into 2028. R&D expenses decreased due to the conclusion of a pivotal program, while G&A expenses increased primarily due to higher compensation.
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, issued a corporate update highlighting recent clinical and regulatory milestones for its drug candidate, lorundrostat, which targets hypertension and related comorbidities. The company announced its participation in the 15th LifeSci Partners Corporate Access event in January 2026, and provided updates on trials, including the upcoming topline results from the Phase 2 Explore-OSA trial and regulatory progress with its NDA submission for lorundrostat in late 2025. Mineralys Therapeutics emphasized lorundrostat's strong safety profile and efficacy across various patient populations, reinforcing its potential as a treatment for uncontrolled and resistant hypertension, chronic kidney disease, and obstructive sleep apnea.
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision
Mineralys Therapeutics Inc. is approaching significant clinical and regulatory milestones for its lead drug candidate, lorundrostat, for difficult-to-treat hypertension. The company expects to report topline results from its Phase 2 Explore-OSA trial in Q1 2026 and confirmed the New Drug Application for lorundrostat with the FDA in late 2025. This follows successful clinical trials demonstrating sustained 24-hour blood pressure control and a favorable safety profile across various patient populations.
Mineralys Therapeutics Insider Sold Shares Worth $9,261,028, According to a Recent SEC Filing
A recent SEC filing reveals that an insider at Mineralys Therapeutics sold shares valued at $9,261,028. This transaction was reported on January 7, 2026, and follows several other insider trading activities for the company in late 2025. Mineralys Therapeutics is a clinical-stage biopharmaceutical company focusing on treatments for hypertension and chronic kidney disease.
New blood pressure drug shows promise for hard-to-treat patients
Mineralys Therapeutics has provided a corporate update highlighting clinical and regulatory milestones for its investigational antihypertensive drug, lorundrostat. The company filed a New Drug Application (NDA) in late 2025 following the successful completion of three positive clinical trials, with pivotal Phase 3 trials meeting their primary endpoints. Topline results for the Phase 2 Explore-OSA trial are anticipated in Q1 2026, further supporting lorundrostat's potential for patients with hypertension and comorbid conditions.
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Mineralys Therapeutics provided a corporate update highlighting recent and upcoming clinical and regulatory milestones for lorundrostat, their proprietary aldosterone synthase inhibitor. The company plans to report topline results from the Phase 2 Explore-OSA trial in Q1 2026 and filed an NDA for lorundrostat in late 2025 following successful clinical programs. Mineralys also announced its participation in the 15th LifeSci Partners Corporate Access event in January 2026.
Mineralys Therapeutics, Inc. Provides Corporate Update and Announces NDA Filing
Mineralys Therapeutics, Inc. announced the filing of a new drug application (NDA) for lorundrostat with the FDA in late 2025. The company also highlighted positive results from multiple clinical trials, including the Explore-CKD trial for reducing systolic BP, and the Launch-HTN and Advance-HTN trials for efficacy and safety in hypertension patients, with topline results from the Phase 2 Explore-OSA trial expected in Q1 2026.
Mineralys Therapeutics, Inc. (MLYS) Investor Outlook: Analyzing a Potential 42.67% Upside in the Biotech Sector
Mineralys Therapeutics, Inc. (MLYS) is attracting investor interest in the biotech sector due to its promising clinical-stage developments, particularly with its drug lorundrostat for cardiorenal conditions. Analysts are highly confident in MLYS, with an average target price suggesting a 42.67% potential upside despite the company being pre-profit and showing recent bearish technical indicators. This outlook positions MLYS as a compelling, albeit high-risk, opportunity for growth-oriented investors.
